Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that a specific subpopulation of umbilical cord-derived mesenchymal stem cells, CMD, may enhance wound healing and tissue quality in chronic skin ulcers, with promising results in both murine and equine models.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This review examines the role of thiopurines in managing inflammatory bowel diseases like ulcerative colitis and Crohn's disease, and reports no new clinical results, emphasizing the need for more studies on thiopurine withdrawal scenarios.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This review discusses major dermatologic conditions occurring in the early post-hematopoietic stem cell transplant period and reports no new clinical results; it underscores dermatologists' role in recognizing critical complications.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

This study found that methanolic extract from Cnicus Benedictus leaves inhibits the growth of human cervical cancer cells in vitro and selectively targets cancer cells over normal cells, suggesting potential safety in its efficacy.

This study found that combining microneedling with clobetasol propionate 0.05% cream significantly improved complete hair regrowth in alopecia areata patches compared to using the cream alone, with nearly double the rate of full hair regrowth observed in the combination treatment group.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study found that topical application of the BRAF inhibitor vemurafenib improved wound healing and promoted hair follicle regeneration in a diabetic murine model.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

In this study, three patients with extensive alopecia areata receiving ustekinumab treatment showed significant hair regrowth and decreased inflammation over 20 weeks, suggesting potential targeted treatment for this condition.

This case report describes a 64-year-old man with advanced colorectal cancer developing cutaneous side effects from panitumumab, highlighting the importance of early diagnosis and treatment to improve quality of life and therapy continuation.

Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

This study found that the collagen-binding fusion protein PTH-CBD significantly improved hair regrowth and follicle health in mice after chemotherapy, suggesting potential as a therapy for chemotherapy-induced alopecia.

In this study, intralesional triamcinolone acetonide combined with 5-fluorouracil was more effective for treating keloids, showing a good to excellent response in 95% of cases and fewer side effects, compared to triamcinolone acetonide alone, which achieved a 70% response rate.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This case study reports that a canine with hepatoid cell carcinoma had a positive health turnaround after one month of biorregulatory therapy, following limited success and adverse effects from metronomic chemotherapy.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.